Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks

Cantor Fitzgerald raised price targets on Eli Lilly ($1,410 to $1,440) and AbbVie ($285 to $290), maintaining Overweight ratings, and on Merck ($120 to $145) and Pfizer ($27 to $28), maintaining Neutral ratings. The firm sees stronger conviction in Lilly and AbbVie, while citing growth, clinical-catalyst, estimate-revision, and—in Pfizer’s case—dividend-sustainability uncertainties. Company results were mixed: Lilly revenue rose 47.7% to $22.97B and its 2026 revenue guidance increased to $85–$87B, while Pfizer cut its 2026 COVID revenue expectation to about $4B.

Analysis

Treat these target increases as a dispersion signal, not a fresh catalyst: unchanged ratings leave the underlying estimate risks intact. The key portfolio distinction is durability of replacement growth versus dependence on a catalyst. Lilly’s premium makes even solid growth vulnerable to multiple compression if pricing, launch uptake, or expectations disappoint; a beat may be needed simply to defend the valuation. AbbVie’s replacement franchises reduce Humira concentration, but below-consensus prescriptions create a near-term revision risk before that longer-term transition is fully trusted. Merck’s strong recent share performance raises the bar for its October 26 event and clinical updates: favorable data could support estimates, while merely adequate news may disappoint. Pfizer’s high yield may attract income buyers, but a trial catalyst cannot by itself settle the separate cash-generation and dividend-capacity question.

Over the next weeks, focus on prescription trends and Merck’s ESMO-related disclosures; through Q4, Pfizer’s prostate-cancer readout is a binary event. Over 6–18 months, the bigger driver is whether Lilly and AbbVie can sustain growth without deteriorating price/mix, and whether Merck’s pipeline can offset future portfolio concentration. Contrarian point: the most interesting risk may be Merck, not Pfizer—recent outperformance plus a neutral stance leaves room for disappointment if estimate revisions fail to materialize. Conversely, a positive Lilly quarter may not generate upside if it only meets elevated expectations.

Key Decisions for Investors

• Do not trade the target changes alone. Consider a modest, catalyst-aware relative position favoring AbbVie over Pfizer only after confirming improving Skyrizi/Rinvoq prescription trends; reassess if they remain below expectations or guidance is constrained. Pfizer short exposure carries dividend and trial-event risk.
• Keep Lilly as a quality-growth exposure, but avoid adding ahead of evidence that demand and pricing support expectations. A meaningful deterioration in prescription momentum or guidance would challenge the premium-multiple thesis; continued execution without estimate upgrades may still cap relative upside.
• For Merck, wait for the October 26 event and relevant ESMO data before chasing year-to-date strength. Falsification of the constructive estimate-revision thesis would be no credible 2027 outlook improvement or clinical results that fail to support pipeline contribution.
• For Pfizer, treat the dividend as a cash-flow underwriting question, not a yield screen. Monitor operating cash generation, payout coverage, and the Q4 prostate-cancer results; worsening coverage or a weaker growth outlook would invalidate an income-oriented hold thesis.